MUC1, excessively overexpressed in over 90% of breast tumors and 60% of captured circulating tumor cells (CTCs) from metastatic breast, lung, pancreatic, and colon cancer patients, holds promise as a biomarker for BC CTCs44–46. This evidence concerns the gene MUC1 and malignant colon neoplasm.